Conversely, the SPDR S&P Biotech ETF displays more volatility, like high-beta stocks.
"History suggests that while S&P is likely to continue rallying from here, high beta will not continue to outperform to the same degree," said Chintan Kotecha, an analyst at BAML, in a note to clients. The same up-then-down pattern has historically occurred within the biotech sector, and provides a way for traders to profit from a likely slowdown in high-beta stocks, Kotecha said.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: CNBC - 🏆 12. / 72 Lire la suite »
La source: CNBC - 🏆 12. / 72 Lire la suite »